Building nicely.. Hope management can continue to improve in effectively communicating the story..
If I were DXB, following good results in July from Phase 2a, I'd be seriously looking at out-licensing opportunities (Chemocentryx plus others). They could co-develop or sell the program and focus on a number of other HIT-platform generated targets. All they need is cash, then make a few good hires and they can then start to truly exploit this great technology that they have.. Then it's a $100M+ company without any dispute..
Ann: Shareholder Briefing, page-83
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $209.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 91570 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 7922 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |